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Abstract  
Enterovirus 71 (EV71) is one of the most virulent agents responsible for Hand, Foot and Mouth Disease (HFMD) which has been 
consistently associated with severe, life-threatening complications in infants and children during outbreaks in the Asia Pacific
region. Neither vaccine nor effective treatment is currently available. 
We have been investigating the use of live attenuated Bordetella pertussis, the agent of whooping cough, to present EV71 vaccine 
candidates to the respiratory mucosa. We have previously shown that B. pertussis BrkA autotransporter could successfully present at 
the bacterial surface a 15 aminoacid (aa) neutralizing B cell epitope from the (EV71) VP1 capsid protein, and triggered in mice a 
strong neutralizing antibody response upon nasal administration of the recombinant bacteria. With the goal to induce an even 
stronger immune response against EV71, we have explored the feasibility to express larger VP1 sub-fragments in attenuated B. 
pertussis using BrkA as carrier.  VP1A and VP1C fragments corresponding to the first N-terminal 62aa and the last C-terminal 98aa 
of VP1, respectively, were fused to the passenger domain of BrkA and were expressed in a highly attenuated strain of B. pertussis
strain. Immunostaining approaches showed that both chimeras were efficiently exposed at the bacterial surface. Furthermore, lung
colonization profiles in mouse displayed by both recombinant strains were comparable to that obtained with the parental strain. Our 
data thus demonstrated that BrkA is a versatile display system that allows surface exposure of large heterologous antigens in B. 
pertussis without major detrimental effects on the outer membrane integrity, host cell viability and lung colonization efficacy of the 
recombinant strains.  
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1. Introduction  
Bordetella pertussis, the etiological agent of whooping cough, colonizes the human respiratory tract very efficiently, 
and triggers strong and protective, local and systemic immune responses upon a single nasal administration (1-4), 
inducing immunity even at distant mucosal sites (5). Recently, a highly attenuated strain of B. pertussis, namely BPZE1 
was constructed (3), with an excellent safety profile in wild type and immuno-compromised mice (3, 6). Furthermore, 
BPZE1 retained the ability to colonize the respiratory tract very effectively, and was shown to induce protective 
immunity against pertussis even more effectively than current acellular pertussis vaccines (3). These features make the 
B. pertussis BPZE1 strain a highly promising live pertussis vaccine candidate, and will shortly enter phase I safety trial 
in humans (http://www.child-innovac.org). In addition, BPZE1 appears to be particularly well-adapted for the nasal 
delivery of heterologous vaccine antigens and represents an attractive mucosal vaccine delivery system. All the foreign 
antigens that have so far been expressed in B. pertussis were fused to the filamentous haemagglutinin (FHA), the main 
B. pertussis adhesin (2, 7-10). However, to be efficiently translocated across the outer membrane and secreted into the 
extracellular milieu, the FHA-based chimeras must remain in an unfolded conformation; specifically, the presence of 
cysteine (Cys) residues in the passenger antigen was shown to impair the chimera secretion due to the formation of 
intramolecular disulfide bonds in the periplasmic space (7, 11). This limitation makes FHA an unsuitable carrier for 
many Cys-containing proteins, calling therefore for the development of other antigen display systems in B. pertussis.
Autotransporters have been successfully used in a variety of microorganisms to present heterologous antigens at the 
bacterial surface (12-15). Autotransporters are large secreted, often virulence-associated proteins of Gram-negative 
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bacteria (16). They perform various functions such as proteolysis, serum resistance, cytotoxicity and adhesion. 
Autotransporters share a common characteristic domain structure that includes: (a) a signal peptide at the N-terminus; 
(b) a passenger domain which encodes for the functional part of the protein; and (c) a C-terminal translocation unit, 
conserved across autotransporters, which encodes a E-barrel that inserts into the outer membrane. Translocation across 
the inner membrane, in all known cases, occurs via the Sec apparatus. Subsequently, the translocation unit forms a E-
barrel structure in the outer membrane, through which the passenger domain is translocated to the cell surface (17). 
Most autotransporters are proteolytically processed, releasing an D-domain which comprises most of the passenger 
domain.
The B. pertussis BrkA autotransporter confers serum resistance by inhibiting the classical pathway of complement 
activation (18) and plays a role in B. pertussis adhesion to, and invasion of host cells (19). Consistent with the model of 
autotransporter secretion, BrkA is expressed as a 103-kDa precursor that is processed during secretion to yield a 73-
kDa N-terminal passenger domain and a 30-kDa C-terminal translocation unit (20). Following translocation, the 
cleaved passenger domain remains tightly associated with the bacterial surface (21). Recently, we showed that BrkA 
can be successfully used as carrier to expose at the surface of BPZE1 bacteria an Enterovirus 71 (EV71) vaccine 
antigen candidate, namely SP70 (22). SP70 is a 15 amino acids (aa) peptide spanning aminoacids 208 to 222 from the 
viral VP1 capsid protein of EV71, and has been shown to contain a neutralizing (23) and protective B-cell epitope (24). 
Three copies of SP70 peptide were fused to the BrkA passenger domain and the resulting BrkA-(SP70)3 chimera was 
successfully exposed at the bacterial surface of BPZE1 (22). Nasal administration of the live recombinant bacteria 
induced in mice strong and sustained systemic neutralizing antibody response against EV71, indicating that BrkA can 
be used as carrier to present heterologous antigens to the respiratory mucosa.  
To further exploit the potential of BrkA as surface-display system, we investigated the capability of BrkA to 
accommodate large, conformational heterologous proteins. We reasoned that bigger portions of the (EV71) VP1 capsid 
protein contain a higher number of sequential and conformational epitopes and therefore should trigger a stronger 
protective immunity against EV71 than the one obtained with the 15 aa-SP70 peptide. Two sub-fragments of the 
(EV71) VP1 capsid protein- VP1A and VP1C, were thus fused to the passenger domain of BrkA, respectively, and 
expressed in attenuated B. pertussis BPZE1 strain. VP1A and VP1C fragments correspond to the first N-terminal 62aa 
and the last C-terminal 98aa of VP1, respectively, and are at least 4 times larger in size than SP70 peptide.  
2. Materials and Methods 
2.1. Bacterial strains and growth conditions 
The bacterial strains used in this study are listed in Table 1. All B. pertussis strains were grown as described 
previously on Bordet-Gengou (BG) agar or in Stainer-Scholte (SS) liquid medium (25).  
Table 1: Bacterial strains used in this study. 
2.2. Construction of recombinant B. pertussis strains 
To circumvent any problems in protein translation due to poor codon usage (26), the original VP1 DNA sequence of 
EV71 strain 41 (5865/SIN/00009), was optimized to B. pertussis codon usage preference. The optimized VP1 (opVP1)
gene was cloned into pBBR1MCS (27) yielding pBBR1MCS3. To generate the BrkA-VP1A construct, VP1A-
encoding DNA fragment was first obtained by amplifying the 60-256 nucleotide (nt) region of opVP1 from 
pBBR1MCS3 using primers 5’-TTGGATCCGACCCAGGCCCT-3’ and 5’ –TTGGATCCCGCTGTCCAG GGT-3’ 
(BamHI sites are underlined). Similarly, to generate the BrkA-VP1C construct, the VP1C-encoding DNA fragment was 
obtained by amplifying the 484-787nt region of opVP1 using primers 5’-TTGGATCCGGAGTCGCGCGA-3’ and 5’-
TTCGGGATCCAGGCGCGCA-3’ (BamHI sites are underlined). Subsequently, BamHI-digested VP1A and VP1C 
gene fragments were inserted into BamHI-opened pUCSY2, a pUC18-derivative which harbors two DNA fragments 
Strain Relevant feature (s) Reference 
BPZE1 
Attenuated Smr BPSM derivative lacking the dnt gene and 
producing inactive pertussis toxin and reduced tracheal 
cytotoxin 
3
BPVP1A2 BPZE1 derivative producing BrkA-VP1A This study 
BPVP1C2 BPZE1 derivative producing BrkA-VP1C This study 
BPSY1 (BrkA 
K/O)
brkA knockout  BPZE1 derivative 22 
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that are homologous to the brkA ORF (22). The resulting plasmids are named pUC-VP1A and pUC-VP1C, 
respectively. Finally, the 2,141-bp HindIII fragment from pUC-VP1A and 2,245-bp HindIII fragment from pUC-VP1C 
were cloned into HindIII-opened suicide plasmid pJQmp200rpsL18 (28), yielding pJQVP1A and pJQVP1C, 
respectively. BPZE1 was electroporated with pJQVP1A and pJQVP1C, respectively, allowing the BrkA-VP1A and 
BrkA-VP1C constructs to integrate into the chromosomal DNA by allelic exchange (29) at the brkA locus, yielding 
recombinant B. pertussis strains BPVP1A2 and BPVP1C2. 
2.3. Immunodetection of BrkA-VP1A and BrkA-VP1C chimeras 
Western blot, flow cytometry analysis and immunofluorescence microscopy were carried out using polyclonal rabbit 
anti-BrkA immune serum as previously described (22).  
2.4. Mice infection 
The mice were kept under specific-pathogen free conditions in individual ventilated cages, and all the experiments 
were carried out according to the guidelines of the National University of Singapore animal study board. Female 9-
week-old Balb/c mice (CARE, NUS) were infected intranasally (in.) with 5x106 colony forming unit (CFU) of the 
different B. pertussis strains in 20Pl as described previously (22). At the indicated time points, four mice per group 
were euthanized, and their lungs were aseptically removed and homogenized in PBS. Serial dilutions from individual 
lung homogenates were plated onto BG agar, and the total numbers of CFU per lung were determined after 4 to 5 days 
incubation at 37qC.
3. Results 
3.1 Production of BrkA-VP1A and BrkA-VP1C chimeras by B. pertussis 
The BrkA passenger domain [A52-H263] portion was replaced by sub-fragments VP1A and VP1C which correspond 
to the first N-terminal 62aa and the last C-terminal 98aa from the capsid protein VP1 of EV71, respectively (Fig. 1A), 
and both constructs were expressed in BPZE1 as described in Math&Meth. section. Production of BrkA-VP1A and 
BrkA-VP1C chimeras by the recombinant strains was analyzed by immunoblotting using anti-BrkA antibodies. Wild 
type and brkA-knockout (BrkA K/O) BPZE1 strains were used as controls. Two bands of 103 kDa and 73 kDa 
molecular weight corresponding to full-length wild-type BrkA and its passenger domain, respectively, were detected in 
the whole-cell extract of BPZE1 (Fig. 1B, Lane 1). Similarly, two bands at 88kDa and 58kDa, corresponding to full-
length BrkA-VP1A and its passenger domain, respectively, were detected in the cell lysate of BPVP1A2 (Fig. 1B, Lane 
2). Two bands at 90kDa and 60kDa, corresponding to the predicted sizes of full-length BrkA-VP1C and its passenger 
domain, respectively, were also detected from the whole-cell extract of BPVP1C2 (Fig. 1B, Lane 3). Despite loading of 
similar total protein amounts, much weaker signals were obtained for both chimeras compared to the signal obtained 
with wild type BrkA, indicating a significantly lower production yield of the chimeras compared to wild type BrkA. No 
bands were detected in the BrkA K/O strain confirming the specificity of the anti-BrkA antibodies (Fig. 1B, Lane 4).  
FIG. 1 Expression of BrkA-VP1A and BrkA-VP1C chimeras in live attenuated B. pertussis BPZE1 strain. (A) Schematic representation of BrkA-
VP1A and BrkA-VP1C chimeras produced by recombinant B. pertussis strains, BPVP1A2 and BPVP1C2, respectively. (B) Western blot detection of 
BrkA-VP1A and BrkA-VP1C chimeras produced by B. pertussis. 20 ȝl of whole cell lysate from 1, BPZE1; 2, BPVP1A2; 3, BPVP1C2 and 4, BrkA 
K/O were analyzed by immunoblotting using polyclonal rabbit anti-BrkA antiserum. Arrows indicate the specific bands detected by the anti-BrkA 
antibodies. 
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Bacterial fitness of the recombinant BPVP1A2 and BPVP1C2 strains was studied in vitro by monitoring their
growth kinetic profile and comparing to the parental BPZE1 and BrkA K/O strains. BPVP1A2 and BPVP1C2 strains 
clearly displayed reduced growth ability over the course of the in vitro culture (Fig. 2), whereby the cultures’ OD600nm
were significantly lower than that obtained for the parental and BrkA K/O strains (Fig. 2). However, extensive 
clumping was noticed in the culture medium inoculated with BPVP1A2 and BPVP1C2 strains. It is thus possible that 
clumps formation, rather than genuine impaired growth ability, is responsible for the apparent reduced bacterial fitness 

















FIG. 2 Growth kinetic profiles of B. pertussis strains in vitro. B. pertussis BPZE1, BPVP1A2, BPVP1C2 and BrkA K/O strains were grown 
overnight in SS medium and fresh media were inoculated at initial OD600nm of 0.15. The cultures were grown at 37°C with shaking (200 rpm). At 
indicated time points, OD600nm were measured as an indication of the growth rate of B. pertussis strains in vitro.
3.3  Cell surface exposure of the BrkA-VP1A and BrkA-VP1C chimeras 
Exposure of the BrkA-VP1A and BrkA-VP1C chimeras at the bacterial surface was investigated by flow cytometry 
using anti-BrkA antibodies on intact (non-permeabilized) BPVP1A2 and BPVP1C2 bacteria. Parental BPZE1 and 
BrkA K/O strains were used as positive and negative controls, respectively. Whereas background signal was obtained 
with BrkA K/O bacteria, the great majority of the parental BPZE1, and recombinant BPVP1A2 and BPVP1C2 cell 
populations were found positive, with differences not statistically significant (Fig. 3B). However, the fluorescence 
intensities obtained with BPVP1A2 and BPVP1C2 bacteria were significantly lower than that obtained for the parental 
strain BPZE1 (Fig. 3C). Consistent with the western blot data (Fig. 1B), FACS analysis thus indicated that the 
expression level of the BrkA chimeras was significantly lower than the wild type BrkA.  
Surface exposure of the BrkA chimeras was further analyzed by immunofluorescence. BPZE1 and BPVP1A2 
displayed strong and comparable fluorescence intensity signals (Fig. 4H & 4I, respectively), whereas a weaker signal 
was obtained with BPVP1C2 cells (Fig. 4J). No significant fluorescence emission was detected with the BrkA K/O 
strain (Fig. 4G). 
Together, our data indicate that majority of the recombinant BPVP1A2 and BPVP1C2 bacteria are able to express 
the BrkA chimeras on their cell surface although at levels lower than the level obtained with the parental BPZE1 strain 
which expresses wild-type BrkA. 
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FIG. 3 Detection of the BrkA-VP1A and BrkA-VP1C chimeras by flow cytometry. Anti-BrkA polyclonal antibodies were co-incubated with intact 
B. pertussis strains as indicated. The parental BPZE1 and BrkA K/O strains were used as positive and negative controls, respectively. The isotype 
control consisted of BPZE1 bacteria stained with Cy2-conjugated secondary antibody. (A) Typical flow cytometry analysis histograms in a 
representative experiment. (B) Average values for the two independent experiments. (C) Mean Fluorescence Intensities of B. pertussis strains 
expressing BrkA protein. Data are expressed as the means ± standard deviation of two independent experiments. Significant statistical differences in 
relation to the BPZE1 group are represented by (*) p <0.05 and (**) p<0.01. 
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FIG. 4 Detection of the BrkA-VP1A and BrkA-VP1C chimeras by immunofluorescence. Anti-BrkA polyclonal antibodies were co-incubated with
intact BrkA K/O (B and G), BPZE1 (C and H), BPVP1A2 (D and I) or BPVP1C2 (E and J) cells. The isotype control (A and F) consisted of BPZE1 
bacteria stained with Cy2-conjugated secondary antibody. Panels A to E show corresponding phase-contrast images.  
3.4  Lung colonization by BPVP1A2 and BPVP1C2
The ability of BPVP1A2 and BPVP1C2 strains to colonize the mouse respiratory tract was investigated and 
compared to the parental BPZE1 strain. 
A significantly lower number of BPVP1A2 and BPVP1C2 bacteria were recovered from the mouse lungs at day 7 
post-infection (p.i.) compared to the parental BPZE1 strain (Fig. 5). However, comparable numbers of CFU were 
obtained at the subsequent time points, i.e. 10 and 17 days p.i. These data demonstrated that recombinant BPVP1A2 
and BPVP1C2 strains colonize efficiently the mouse respiratory tract, thereby suggesting that both strains should be 
able to prime effectively the host immune system at the nasal and respiratory mucosa. 










FIG. 5 Lung colonization by recombinant B. pertussis strains. Mice were infected intranasally with 2 x 106 CFU of BPZE1, BPVP1A2 and 
BPVP1C2 strains at 0 h. The lungs were harvested at the indicated time points, and the number of viable bacteria was determined after plating 
appropriate dilutions of the lung homogenates onto BG agar. Four mice per group per time point were assessed individually. Significant statistical 
differences in relation to the BPZE1 group are represented by (*) p <0.05.  
4. Discussion 
Gram-negative bacteria have evolved various systems to transport proteins to the cell surface or secrete them into 
the extracellular milieu. Among these systems, autotransporters represent a solution of remarkable simplicity, as all 
information required for transport to the outer membrane and secretion is contained in the primary sequence itself (17). 
Several autotransporters have been employed to express heterologous antigens at the bacterial surface (12-15). In 
addition to their inherent simplicity, autotransporters offer several advantages as a heterologous protein display system. 
Studies showed that autodisplay enables the recombinant expression of more than 105 proteins or peptide molecules on 
the surface of E. coli without reducing cell viability or integrity of the recombinant bacteria (15, 30-31), thus making 
autotransporters a high-valency display system of heterologous proteins (32). Furthermore, the mobility of the protein’s 
ȕ-barrel in the outer membrane enables passenger domains to form multimers at the cell surface (33-34). This special 
feature may be advantageous for the heterologous expression of proteins whose functionality requires multimerization. 
Altogether, these features make autotransporters obvious candidates as surface display systems for a wide range of 
biotechnological and biomedical applications (32).  
Efficient surface expression of heterologous proteins using autotransporters as carrier appears to be multifactorial. 
Protein size and conformation are reported to greatly influence the success of the translocation process. Large proteins 
tightly folded or containing internal disulphide bonds are indeed in general more challenging to translocate through the 
E-barrel of the transport unit. However, although autotransporters share the same structural domain organization, their 
structural tolerance to translocate heterologous proteins across the outer membrane varies from one to another. The 
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(CtxB) subunit which forms internal disulphide bonds (35). But the same autotransporter was reported to successfully 
transport single chain variable antibody domains in an active conformation with disulphide bonds preformed in the 
periplasm (36). Likewise the presence of cysteine bridges within the FimH lectin domain did not interfere with its 
surface display using the E. coli Ag43 autotransporter (37). Therefore, structural tolerance of autotransporters to 
translocate heterologous proteins across the outer membrane remains difficult to predict. 
A previous study showed that deletion of amino acid residues A52 to P600 in the passenger domain of the B.
pertussis BrkA autotransporter does not impair translocation and surface exposure of the protein (38). This finding thus 
prompted us to use BrkA as a carrier by replacing part of the A52-P600 region in the passenger domain with 
heterologous vaccine candidates. Here the [A52-H263] portion of the BrkA passenger domain was replaced by the N-
terminal VP1A and C-terminal VP1C protein fragments of (EV71) VP1 capsid. Our data indicate that the BrkA 
chimeras were successfully produced and exposed at the bacterial surface of BPZE1, although with a lesser efficiency 
than the wild type BrkA molecules. The chimeras being smaller than wild type BrkA, size cannot be accounted for the 
lower production yield observed. Instead, the conformation of the recombinant passenger domains in the chimeras is 
likely to be different from the BrkA wild type conformation and may thus affect translocation efficacy across the outer 
membrane, thereby resulting in exposure of fewer molecules at the bacterial surface and degradation of the improperly 
folded chimeras. In addition, the presence of one Cys residue at position 63aa in VP1C fragment may also lead to the 
formation of intermolecular disulfide bonds in the perisplasmic space and impair the translocation efficacy of the 
dimerized recombinant proteins across the outer membrane. Consistently, production yield and surface-exposure of the 
BrkA-VP1C chimera were found to be the most impaired when compared to the BrkA-VP1A chimera and wild type 
BrkA.
In conclusion, this work shows that the B. pertussis BrkA autotransporter can support the surface exposure of large, 
conformational Cys-containing foreign inserts, although with lower efficacy compared to the wild type BrkA protein. 
Importantly, the BrkA chimeras can be displayed at the cell surface without significant detrimental effect on the 
bacterial colonization ability since both recombinant strains were able to persist for more than 14 days in the murine 
respiratory tract, which likely ensures efficient priming of the host immune system. The ability of the recombinant 
BPVP1A and BPVP1C2 strains at inducing specific cellular and humoral protective immune responses in mice upon 
nasal administration of the live recombinant bacteria is currently underway. The efficient presentation to the mucosal 
immune system of EV71 vaccine candidates expressed at the cell surface of an attenuated strain of B. pertussis 
provides an innovative approach to induce simultaneous protection against two childhood diseases, namely whooping 
cough and Hand, Foot and Mouth disease. 
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